News | Contrast Media | June 01, 2020

FDA Approves TAUVID for Use in Patients Being Evaluated for Alzheimer’s Disease

The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD). A neuropathological diagnosis of AD requires the demonstration of the presence of both beta-amyloid neuritic plaques and tau NFTs in the brain. TAUVID is the first and only approved diagnostic agent to image tau NFTs in the brain. Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company, developed TAUVID and AMYVID (Florbetapir F 18 Injection) to provide physicians with meaningful information on the presence of both pathologies to aid the evaluation of patients suspected of having AD.

“The use of diagnostic imaging can help patients and their families plan for the future and make informed choices about their health and well-being, in addition to facilitating appropriate patient management for physicians,” said Reisa Sperling, M.D., Professor of Neurology of Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. “Determining the anatomic distribution and density of tau NFTs in the brain was previously possible only at autopsy. Now we have a way to obtain this important information in patients.”

TAUVID was evaluated in two clinical studies. In Study 1, reader interpretations of premortem TAUVID scans from 64 cognitively normal and impaired terminally ill patients who agreed to undergo TAUVID imaging and to participate in a postmortem brain donation program were compared to tau pathology at autopsy based on scoring provided by independent pathologists blinded to scan results. This study met its pre-specified success criteria, with reader sensitivity (95% CI) ranging from 92% (80, 97) to 100% (91, 100) and specificity (95% CI) from 52% (34, 70) to 92% (75, 98) in the primary efficacy cohort. In Study 2, images from the same terminally ill patients as in Study 1 (plus 18 additional terminally ill patients) and 159 patients with cognitive impairment being evaluated for AD (the indicated population) were evaluated by 5 new readers. This study also met the prespecified success criteria for comparison of TAUVID reads to NFT pathology. In addition, inter-reader agreement was evaluated using Fleiss’ kappa statistic and found to be 0.87 (95% CI: 0.83, 0.91) across 241 patients in Study 2. The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).

“The fight against AD requires precise and reliable assessments of the two key pathologies of the disease because clinical assessments alone are limited in their ability to accurately diagnose patients,” said Mark Mintun, M.D., vice president of Lilly’s pain and neurodegeneration research and development. “History was made with the FDA approval of AMYVID to demonstrate the presence of one of those two pathologies, beta-amyloid plaques. I am excited that TAUVID has now been approved to image tau NFTs, which is the other key pathology, allowing a more comprehensive evaluation of patients. Lilly and Avid Radiopharmaceuticals are committed to bringing innovative AD diagnostics to the patients who need them most.”

Availability of TAUVID will initially be limited and will expand in response to commercial demand and payor reimbursement. Lilly remains committed to patients with cognitive impairment associated with Alzheimer’s disease and to ensuring patient access to this innovative diagnostic tool. Lilly is supportive of policies that will provide access and coverage for beta-amyloid PET and tau PET imaging agents.

For more than 30 years, Lilly has been engaged in bringing innovative Alzheimer’s disease therapies and diagnostics to patients and continues to lead the field in research, which also includes identifying biomarkers to support early detection of the disease.

For more information: www.lilly.com

Related Content

Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.
a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology

a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Radiology Imaging | August 14, 2020
August 14, 2020 — According to ARRS' ...
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.
A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Results of Journal of the American College of Surgeons study should reassure breast cancer patients who experienced surgical postponements due to COVID-19 pandemic

Association between Time to Operation and Pathological Stage in DCIS & ER+ Breast Cancer. Courtesy of American College of Surgeons

News | Women's Health | August 07, 2020
August 7, 2020 — A new br...

An oncologist practices social distancing while talking to a cancer patient. Image courtesy of University of Michigan Rogel Cancer Center

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — When COVID-19 struck, health ca
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
According to the new market research report "Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) - Global Forecast to 2025", published by MarketsandMarkets, the radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9%.

Courtesy of MarketsandMarkets Research

News | Radiation Dose Management | August 03, 2020
August 3, 2020 — According to the new market research report "...